Loading
Life sciences · Interventional Study
ClinicalTrials.gov · November 2, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Interventional Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07908953). This is a study registration, not published results. Lead sponsor: Antony Barbosa Institute. Recruitment status: NOT_YET_RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 150 participants (ESTIMATED). Conditions: Skin Laxity, Localized Adiposity, Cellulite, Tissue Fibrosis, Pathological Scarring. Interventions: DRUG: Recombinant Hyaluronic Acid (pbserum HA 2.0®); DRUG: pbserum Plus®. Primary outcome measures: Clinical Safety , From the intervention through Day 180; Change in Skin Elasticity Measured by Cutometry , Baseline and Day 180; Change From Baseline in Subcutaneous Fat Thickness Measured by Ultrasonography , Baseline and Day 90; Change in Treated-Area Volume , Baseline and Day 90; Change From Baseline in Cellulite Severity Scale Score , Baseline and Day 180. Brief summary: This study will evaluate the efficacy and safety of recombinant enzymes contained in pbserum Plus® and pbserum HA 2.0® for aesthetic and regenerative tissue bioremodeling. The study will include adult participants with clinical conditions such as facial or body skin laxity, localized adiposity, cellulite, tissue fibrosis, subcutaneous nodules, and pathological scars. Participants will be evaluated according to the specific clinical condition being treated. The study will assess changes in the treated tissues using clinical evaluations, standardized photographs, patient and evaluator assessments, validated questionnaires, ultrasonography, elastography, cutometry, and three-dimensional imaging when applicable. Participants will be followed longitudinally after treatment, with evaluations at different time points to monitor clinical changes, aesthetic outcomes, satisfaction, and safety. Possible adverse events and treatment-related complications will also be recorded throughout the study. The study aims to determine whether recombinant enzyme-based treatments can provide clinical improvement while maintaining an acceptable safety profile and to generate scientific evidence regarding their use in aesthetic and regenerative medicine.